Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Nathan Williams

Gynecology Asheville, NC Medical Doctor

NPI 1093774234 CMS profile 4826

53 S French Broad Ave Ste 200, Asheville, NC 28801

Open in the dashboard

General payments

$8,210

376 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Nathan Williams of Asheville, NC is reported in the CMS Open Payments database as having received $8,210 across 376 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 90th percentile of Gynecology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $907 37
2024 General $1,254 55
2023 General $1,322 59
2022 General $1,162 49
2021 General $1,940 79
2020 General $810 45
2019 General $815 52

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Nathan Williams
  • Gynecology median
  • Middle half of Gynecology
  • National median

In program year 2025, general payments to Nathan Williams were reported at $907. Among 1,279 Gynecology profiles paid that year, the median was $162 and the middle half received between $56 and $501.

Show as a table
Year Nathan Williams Gynecology median Middle half National median
2019 $815 $199 $66–$472 $163
2020 $810 $114 $42–$287 $114
2021 $1,940 $141 $42–$430 $132
2022 $1,162 $173 $52–$532 $149
2023 $1,322 $170 $57–$501 $160
2024 $1,254 $157 $50–$424 $164
2025 $907 $162 $56–$501 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Novartis Pharmaceuticals Corporation $2,612 73 payments
  2. Pfizer Inc. $775 59 payments
  3. Daiichi Sankyo Inc. $684 31 payments
  4. Lilly USA, LLC $617 34 payments
  5. AstraZeneca Pharmaceuticals LP $517 25 payments
  6. Merck Sharp & Dohme Corporation $422 19 payments
  7. Amgen Inc. $293 12 payments
  8. Seattle Genetics, Inc. $256 15 payments
  9. Gilead Sciences, Inc. $250 14 payments
  10. GlaxoSmithKline, LLC. $225 11 payments
  11. Other $1,560 83 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $6,927 359 payments
  2. Long term medical supply or device loan $1,198 13 payments
  3. Education $85 4 payments
Products named General payments · program years 2019–2025
  1. KISQALI $2,093 55 payments
  2. IBRANCE $764 58 payments
  3. VERZENIO $617 34 payments
  4. ENHERTU $515 24 payments
  5. TUKYSA $446 24 payments
  6. KEYTRUDA $403 18 payments
  7. TALZENNA $346 35 payments
  8. PIQRAY $308 14 payments
  9. ZEJULA $297 14 payments
  10. XGEVA $236 9 payments
  11. Other $3,572 186 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 14 drugs

Part D claims

390

Median for Obstetrics & Gynecology: 65

Drug cost

$1,066,728

Median for Obstetrics & Gynecology: $3,585

Branded share of claims

39.2%

Median for Obstetrics & Gynecology: 25.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Kisqali Ribociclib Succinate Brand 46 $644,104
Ibrance Palbociclib Brand 25 $405,979
Eliquis Apixaban Brand 17 $11,443
Tamoxifen Citrate Generic 98 $2,682
Letrozole Generic 39 $944
Anastrozole Generic 37 $617
Lidocaine-Prilocaine Lidocaine/Prilocaine Brand 16 $206
Potassium Chloride Generic 14 $174
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 19 $167
Celecoxib Generic 26 $145

The 10 drugs with the highest cost, of 14 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 24,311 Part D prescribers listed as Obstetrics & Gynecology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 122 billing codes

Paid by Medicare

$692,094

Of which drugs: $519,402

Medicare patients

547

Average age 75

Services billed

41,734

451 women, 96 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 66%
Cancer 53%
Arthritis 45%
Osteoporosis 25%
Depression 24%
Diabetes 23%
Chronic kidney disease 16%
Atrial fibrillation 15%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, fulvestrant, 25 mg J9395 Office 14 1,880 $11,762
Injection, zoledronic acid, 1 mg J3489 Office 13 144 $714
Infusion, normal saline solution , 1000 cc J7030 Office 13 59 $120
Injection, dexamethasone sodium phosphate, 1 mg J1100 Office 12 660 $58
Infusion, normal saline solution, sterile (500 ml = 1 unit) J7040 Office 17 54 $54

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 10 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
KISQALI
  • Novartis Pharmaceuticals Corporation $450
$450 46 —
ENHERTU
  • Daiichi Sankyo Inc. $139
  • AstraZeneca Pharmaceuticals LP $122
$262 — —
VERZENIO
  • Lilly USA, LLC $99
$99 — —
IBRANCE
  • PFIZER INC. $99
$99 25 —
PROVENGE
  • Dendreon Pharmaceuticals LLC $80
$80 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 10 in the dashboard with a free account

Records

376 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Gynecology in North Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record